Eli Lilly & Co (1LLY) Stock Forecast & Price Target

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1LLY Analyst Ratings

Strong Buy

18 Buy

2 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1LLY Stock 12 Month Forecast

Average Price Target

€1,190.68

▲(11.38% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is €1,190.68 with a high forecast of €1,384.74 and a low forecast of €982.30. The average price target represents a 11.38% change from the last price of €1,069.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"615":"€615","1000":"€1,000","1385":"€1,385","807.5":"€807.5","1192.5":"€1,192.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1384.735888,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.38K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1190.6805392511112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":982.29702055,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€982.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[615,807.5,1000,1192.5,1385],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,993.6,1023.687376,1053.774752,1083.862128,1113.949504,1144.03688,1174.124256,1204.211632,1234.299008,1264.386384,1294.4737599999999,1324.5611359999998,1354.648512,{"y":1384.735888,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,993.6,1008.7600414808547,1023.9200829617095,1039.080124442564,1054.2401659234188,1069.4002074042735,1084.5602488851282,1099.720290365983,1114.8803318468376,1130.0403733276924,1145.200414808547,1160.3604562894018,1175.5204977702565,{"y":1190.6805392511112,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,993.6,992.7305400423077,991.8610800846154,990.9916201269231,990.1221601692308,989.2527002115385,988.3832402538461,987.5137802961539,986.6443203384615,985.7748603807692,984.9054004230769,984.0359404653846,983.1664805076923,{"y":982.29702055,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":651.786,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 79,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616.269,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":688.812,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":739.363,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":914.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":912.876,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":888.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":883.671,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":823.276,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":785.142,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":923.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1044.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":993.6,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1,385

Average Price Target€1,191

Lowest Price Target€982.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emily Field

Barclays

€1,211.64

Buy

13.34%

Upside

Reiterated

08/10/26

Analysts Conflicted on These Healthcare Names: Evolent Health (NYSE: EVH), Eli Lilly & Co (NYSE: LLY) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Srikripa Devarakonda

Truist Financial

€1,185.68→€1,190.87

Buy

11.40%

Upside

Reiterated

08/07/26

Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

€1,165.77→€1,228.09

Buy

14.88%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,419 from $1,347 at Morgan StanleyEli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley

Evan Seigerman

BMO Capital

€1,125.1→€1,211.64

Buy

13.34%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,400 from $1,300 at BMO CapitalEli Lilly price target raised to $1,400 from $1,300 at BMO Capital

Asad Haider

Goldman Sachs

€1,110.39→€1,183.08

Buy

10.67%

Upside

Assigned

08/06/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

€1,198.66

Buy

12.13%

Upside

Reiterated

08/06/26

Eli Lilly Outperformance and Incretin Momentum Support Buy Rating with Unchanged $1,385 Price Target

Chris Schott

J.P. Morgan

€1,211.64

Buy

13.34%

Upside

Assigned

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), MannKind (NASDAQ: MNKD) and Evolus (NASDAQ: EOLS)

Louise Chen

Scotiabank

€1,125.1

Buy

5.25%

Upside

Reiterated

08/06/26

Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Carter Gould

Cantor Fitzgerald

€1,168.37→€1,220.3

Buy

14.15%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,410 from $1,350 at Cantor FitzgeraldEli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Jason Gerberry

Bank of America Securities

€1,154.52→€1,163.18

Buy

8.81%

Upside

Reiterated

08/05/26

Eli Lilly Buy Rating Reaffirmed as Obesity Leadership Drives Outlook; Price Target Raised to $1,344 from $1,334

Trung Huynh

RBC Capital

€1,298.19

Buy

21.44%

Upside

Reiterated

08/05/26

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Mohit Bansal

Wells Fargo

€1,107.79→€1,151.06

Buy

7.68%

Upside

Assigned

08/05/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Envista Holdings (NYSE: NVST) and Akebia Therapeutics (NASDAQ: AKBA)

Michael Yee

UBS

€1,233.28

Buy

15.37%

Upside

Reiterated

08/05/26

Michael Yee Reiterates Buy Rating and Maintains $1,425 Price Target on Strong Earnings Power and Obesity Portfolio Momentum

David Risinger

Leerink Partners

―

Buy

―

Reiterated

07/17/26

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emily Field

Barclays

€1,211.64

Buy

13.34%

Upside

Reiterated

08/10/26

Analysts Conflicted on These Healthcare Names: Evolent Health (NYSE: EVH), Eli Lilly & Co (NYSE: LLY) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Srikripa Devarakonda

Truist Financial

€1,185.68→€1,190.87

Buy

11.40%

Upside

Reiterated

08/07/26

Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Terence Flynn

Morgan Stanley

€1,165.77→€1,228.09

Buy

14.88%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,419 from $1,347 at Morgan StanleyEli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley

Evan Seigerman

BMO Capital

€1,125.1→€1,211.64

Buy

13.34%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,400 from $1,300 at BMO CapitalEli Lilly price target raised to $1,400 from $1,300 at BMO Capital

Asad Haider

Goldman Sachs

€1,110.39→€1,183.08

Buy

10.67%

Upside

Assigned

08/06/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

€1,198.66

Buy

12.13%

Upside

Reiterated

08/06/26

Eli Lilly Outperformance and Incretin Momentum Support Buy Rating with Unchanged $1,385 Price Target

Chris Schott

J.P. Morgan

€1,211.64

Buy

13.34%

Upside

Assigned

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (NYSE: LLY), MannKind (NASDAQ: MNKD) and Evolus (NASDAQ: EOLS)

Louise Chen

Scotiabank

€1,125.1

Buy

5.25%

Upside

Reiterated

08/06/26

Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Carter Gould

Cantor Fitzgerald

€1,168.37→€1,220.3

Buy

14.15%

Upside

Reiterated

08/06/26

Eli Lilly price target raised to $1,410 from $1,350 at Cantor FitzgeraldEli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald

Umer Raffat

Evercore ISI

―

Hold

―

Reiterated

08/06/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Jason Gerberry

Bank of America Securities

€1,154.52→€1,163.18

Buy

8.81%

Upside

Reiterated

08/05/26

Eli Lilly Buy Rating Reaffirmed as Obesity Leadership Drives Outlook; Price Target Raised to $1,344 from $1,334

Trung Huynh

RBC Capital

€1,298.19

Buy

21.44%

Upside

Reiterated

08/05/26

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Mohit Bansal

Wells Fargo

€1,107.79→€1,151.06

Buy

7.68%

Upside

Assigned

08/05/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Envista Holdings (NYSE: NVST) and Akebia Therapeutics (NASDAQ: AKBA)

Michael Yee

UBS

€1,233.28

Buy

15.37%

Upside

Reiterated

08/05/26

Michael Yee Reiterates Buy Rating and Maintains $1,425 Price Target on Strong Earnings Power and Obesity Portfolio Momentum

David Risinger

Leerink Partners

―

Buy

―

Reiterated

07/17/26

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

Geoff MeachamCiti

Success Rate

33/44 ratings generated profit

Average Return

+11.56%

Copying Geoff Meacham's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +11.56% per trade.

1 Year

Geoff MeachamCiti

Success Rate

43/44 ratings generated profit

Average Return

+43.04%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +43.04% per trade.

2 Years

Geoff MeachamCiti

Success Rate

44/44 ratings generated profit

Average Return

+67.13%

Copying Geoff Meacham's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +67.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1LLY Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1LLY has received 59 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 1LLY average Analyst price target in the past 3 months is 1,190.68.

Each month's total comprises the sum of three months' worth of ratings.

1LLY Financial Forecast

1LLY Earnings Forecast

Next quarter’s earnings estimate for 1LLY is €8.45 with a range of €7.75 to €9.78. The previous quarter’s EPS was €7.25. 1LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 37.93% of the time in the same period. In the last calendar year 1LLY has Performed in-line its overall industry.

1LLY Sales Forecast

Next quarter’s sales forecast for 1LLY is €19.11B with a range of €18.16B to €20.81B. The previous quarter’s sales results were €19.88B. 1LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year 1LLY has Performed in-line its overall industry.

1LLY Stock Forecast FAQ

What is IT:1LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,190.68.

What is IT:1LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 11.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly & Co a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 18 buy ratings, 2 hold ratings and 0 sell ratings.

What is Eli Lilly & Co’s share price target?

The average share price target for Eli Lilly & Co is 1,190.68. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1,384.74 ,and the lowest forecast is €982.30. The average share price target represents 11.38% Increase from the current price of €1,069.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Eli Lilly & Co?

To buy shares of IT:1LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (1LLY) Stock Forecast & Price Target

1LLY Analyst Ratings

1LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

1LLY Analyst Recommendation Trends

1LLY Financial Forecast

1LLY Earnings Forecast

1LLY Sales Forecast

1LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts